NLS Pharmaceutics CEO Outlines Significant Progress and Future Plans in Shareholder Letter
NLS Pharmaceutics CEO Outlines Significant Progress and Future Plans in Shareholder Letter
NLS Pharmaceutics Ltd. (NASDAQ: NLSP), a Swiss company dedicated to developing cutting-edge therapies for central nervous system (CNS) disorders, has recently documented its significant strides and forthcoming initiatives in a letter addressed to its shareholders. This overview primarily highlights five crucial areas of advancement, showcasing the company’s robust performance and ambitious future goals.
1. Major Financing Events Completion
In the initial quarter of 2025, NLS secured two substantial equity financing transactions, raising a combined total of $2.5 million. Shares were priced at $3.10 and $1.65, both surpassing the market value at the time, reflecting premium mark-ups of 48% and 10% respectively. Additionally, a noteworthy $25 million commitment has been established to support a merger with Kadimastem Ltd. (TASE: KDST), aimed at bolstering clinical programs.
Since announcing this merger, NLS has amassed over $6 million to facilitate the impending combination and its subsequent clinical trials. By converting existing liabilities into equity, the firm has significantly improved its financial health, positioning itself as a debt-free entity. These financing successes have not only fortified NLS's balance sheet but also extended its operational cash runway, enabling a sustained focus on research and development (R&D).
2. Positive Clinical and Preclinical Developments
February 2025 marked a turning point for NLS as the company revealed promising preclinical results for its AEX–2 project. This data reinforces the dual orexin receptor agonist platform, which has transformative potential for central nervous system disorders. Furthermore, alongside Kadimastem, NLS successfully completed a Pre-IND Meeting with the U.S. FDA regarding a Type 1 diabetes treatment, laying the groundwork for potential collaboration in future therapies.
In April 2025, the results from Study KO–943 indicated that Mazindol ER effectively diminished fentanyl-induced reward behaviors in animal studies. These findings not only establish vital safety benchmarks but also underscore the therapeutic promise as the company gears up for the next phase of clinical trials.
3. The Kadimastem Merger: Strategic Synergy in Action
In January 2025, following favorable board decisions, Kadimastem shareholders voted overwhelmingly in support of the merger with NLS. This pivotal cooperation is positioned to combine each entity’s unique strengths, fostering innovative treatment options for patients, specifically concerning diabetes and related complexities. Executive Chairman Ronen Twito emphasized the merger’s commitment to enhancing patient care and long-term shareholder value, with a cohesive plan for integration post-merger.
New corporate filings have been initiated to ensure compliance with regulatory standards, and NLS anticipates completing the merger by early Q3 2025.
4. The New Corporate Identity
Upon finalizing the merger, the newly formed organization will be known as NewcelX. This entity aims to become a Nasdaq-listed clinical-stage biotech company with an extensive pipeline that includes:
- - AstroRx®, targeting amyotrophic lateral sclerosis (ALS) in Phase IIa trials,
- - IsletRx, a promising treatment for diabetes,
- - Ongoing development of CNS disorder therapies via the DOXA platform.
5. Setting Future Directions
As the merger completion approaches, NLS prepares to expedite several significant initiatives, including:
- - Launching a multi-site Phase IIa clinical trial for AstroRx® aimed at ALS treatment,
- - Initiating a Phase I clinical study for IsletRx targeting Type I diabetes,
- - Progressing preclinical research for AEX–2/AEX–41 towards late-stage development, focusing on narcolepsy and neurodegeneration.
This impending merger signifies a transformative moment, melding NLS’s innovative DOXA platform with Kadimastem’s stem cell therapies—all under a single operational umbrella, with a strengthened board and financial backing further steering its R&D path.
Conclusion
In his closing remarks, CEO Alexander C. Zwyer celebrated the trust and resilience of NLS shareholders, affirming the upcoming merger’s potential to unlock new capabilities and drive progressive value creation. With the merger on the horizon, NLS anticipates entering an invigorated phase of integration and clinical promise, continually prioritizing pipeline diversification and enhancing long-term value for stakeholders.
For further information on NLS Pharmaceutics and to stay updated on their advancements, visit NLS Pharmaceutics.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.